Nephrocare Health Services Limited (BOM:544647)

India flag India · Delayed Price · Currency is INR
734.00
+11.15 (1.54%)
At close: Jun 19, 2026
Market Cap72.69B
Revenue (ttm)9.99B +128.4%
Net Income768.40M
EPS8.10
Shares Out n/a
PE Ratio94.60
Forward PE44.17
Dividendn/a
Ex-Dividend Daten/a
Volume8,142
Open729.70
Previous Close722.85
Day's Range722.00 - 738.20
52-Week Range445.00 - 767.95
Betan/a
AnalystsBuy
Price Target771.25 (+5.08%)
Earnings DateJul 24, 2026

About BOM:544647

Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India. [Read more]

Industry Miscellaneous Health And Allied Services, Not Elsewhere Classified
Founded 2009
Employees 3,448
Stock Exchange Bombay Stock Exchange
Ticker Symbol 544647
Full Company Profile

Financial Performance

In fiscal year 2026, BOM:544647's revenue was 9.99 billion, an increase of 32.16% compared to the previous year's 7.56 billion. Earnings were 768.40 million, an increase of 14.52%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 544647 stock is "Buy." The 12-month stock price target is ₹771.25, which is an increase of 5.08% from the latest price.

Price Target
₹771.25
(5.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nephrocare Health Services Transcript: Q4 25/26

FY 2026 saw 32% revenue growth and 75% adjusted PAT growth, driven by international expansion, higher treatment volumes, and improved margins. The network now spans 524 clinics across five countries, with strong cash flow and disciplined capital allocation supporting continued growth.

4 weeks ago - Transcripts

Nephrocare Health Services Quarterly report: Q4 2026

Nephrocare Health Services has published its Q4 2026 quarterly earnings report on May 20, 2026.

4 weeks ago - Filings

Nephrocare Health Services Transcript: Q3 25/26

Revenue grew 32% YoY in Q3 and 37% for nine months FY 2026, with international business now 41% of revenue. Adjusted EBITDA margin rose to 24.3%, and ROCE is projected to reach 24.7%. Guidance is for 15%-20% revenue CAGR over 3-4 years.

4 months ago - Transcripts

Nephrocare Health Services Quarterly report: Q3 2026

Nephrocare Health Services has published its Q3 2026 quarterly earnings report on February 11, 2026.

4 months ago - Filings

Nephrocare Health Services Slides: Q3 2026

Nephrocare Health Services has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 11, 2026.

4 months ago - Filings

Nephrocare Health Services Quarterly report: H1 2026

Nephrocare Health Services has published its H1 2026 quarterly earnings report on December 8, 2025.

7 months ago - Filings